(Forbes)
Deliveries of the vital childhood cancer drug vincristine, which is currently in very short supply across the U.S. should resume in late October, according to a new statement from the FDA. However, the drug is still predicted to be in short supply until at least December, indicating that the October deliveries will not solve the issue completely.
Pfizer is the sole manufacturer of the drug in the U.S. after Teva Pharmaceutical made a “business decision” to cease production in July and has been trying to scale up production after experiencing its own manufacturing issues.
Parents of children with cancer have been reacting with shock at the news with many wanting answers as to how this could have happened and when the issue will be resolved. Read more
Comments